Compare Illumina, Inc. (ILMN) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs NICE Ltd — how do they compare? Illumina, Inc. trades at $189.96 (market cap $27.94B), while NICE Ltd trades at $96.15 (market cap $5.91B). The key difference: Illumina, Inc. is far larger — about 4.7× NICE Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | NICE | |
|---|---|---|
Market Cap | $27.94B | $5.91B |
Sector | Health | Technology |
52-Week High | $194.33 | $170.37 |
52-Week Low | $91.00 | $83.15 |
Enterprise Value | $29.33B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
NICE trades at $101.34, up 1.19% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.57% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights AI-driven customer engagement expansions, including a partnership with Banco do Brasil announced on July 14, 2026.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include a projected decline in net income for 2026 and competitive pressures in the technology sector. The absence of sell ratings from analysts underscores underlying strength, but investors should monitor execution against future earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
